Clorox (NYSE:CLX) PT Raised to $137.00

Clorox (NYSE:CLX) had its target price boosted by investment analysts at Barclays from $130.00 to $137.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Barclays‘s target price indicates a potential downside of 14.54% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Citigroup raised their price target on Clorox from $165.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. TD Cowen began coverage on Clorox in a research report on Tuesday, July 23rd. They set a “sell” rating and a $122.00 target price on the stock. DA Davidson reiterated a “neutral” rating and set a $153.00 target price on shares of Clorox in a research report on Friday, September 6th. BNP Paribas upgraded Clorox to a “strong sell” rating in a research report on Friday, September 6th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Clorox from $144.00 to $151.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Six analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $150.36.

Clorox Stock Performance

CLX stock opened at $160.30 on Friday. The company has a market cap of $19.91 billion, a P/E ratio of 83.06, a price-to-earnings-growth ratio of 3.19 and a beta of 0.41. Clorox has a 1 year low of $114.68 and a 1 year high of $169.09. The company has a debt-to-equity ratio of 5.04, a current ratio of 1.03 and a quick ratio of 0.63. The stock’s fifty day moving average price is $157.36 and its 200-day moving average price is $144.78.

Clorox (NYSE:CLX) last released its quarterly earnings results on Thursday, August 1st. The company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.28. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.97 billion. Clorox had a return on equity of 281.12% and a net margin of 3.95%. On average, equities analysts forecast that Clorox will post 6.64 earnings per share for the current year.

Insider Transactions at Clorox

In other news, EVP Angela C. Hilt sold 1,733 shares of Clorox stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $165.52, for a total value of $286,846.16. Following the sale, the executive vice president now directly owns 13,471 shares of the company’s stock, valued at approximately $2,229,719.92. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.51% of the company’s stock.

Institutional Investors Weigh In On Clorox

Several large investors have recently added to or reduced their stakes in CLX. Van ECK Associates Corp boosted its position in shares of Clorox by 1,715.5% during the second quarter. Van ECK Associates Corp now owns 1,461,207 shares of the company’s stock valued at $199,411,000 after buying an additional 1,380,724 shares during the period. Nuance Investments LLC boosted its position in shares of Clorox by 150.6% during the second quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock valued at $218,035,000 after buying an additional 960,094 shares during the period. Confluence Investment Management LLC purchased a new position in shares of Clorox during the first quarter valued at approximately $135,630,000. Wulff Hansen & CO. boosted its position in shares of Clorox by 13,547.0% during the second quarter. Wulff Hansen & CO. now owns 440,116 shares of the company’s stock valued at $60,063,000 after buying an additional 436,891 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of Clorox by 26.5% during the first quarter. Acadian Asset Management LLC now owns 882,526 shares of the company’s stock valued at $135,099,000 after buying an additional 184,847 shares during the period. 78.53% of the stock is owned by institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.